Low‐dose decitabine plus venetoclax is safe and effective as post‐transplant maintenance therapy for high‐risk acute myeloid leukemia and myelodysplastic syndrome

Yunxiong Wei(Tianjin First Center Hospital), Mingfeng Zhao(Tianjin First Center Hospital), Wenyi Lu(Tianjin First Center Hospital), Xia Xiong(Guangzhou University of Chinese Medicine), Xin Jin(Nankai University), Ting Yuan(Goethe University Frankfurt), Xin Li(Central South University), Xiaoyuan He(Nankai University), Rui Sun(Nankai University), Tongtong Sun(Tianjin First Center Hospital), Hairong Lyu(Tianjin First Center Hospital)
Cancer Science
June 29, 2021
Cited by 71


Related Papers